Navigation Links
Researchers find possible clues to tamoxifen resistance in breast cancer patients
Date:3/30/2011

Breast cancer patients who become resistant to tamoxifen may have low levels of a protein called Rho GDI-alpha, according to a study published online March 30 in the Journal of the National Cancer Institute.

Women whose tumors have estrogen receptors (ERs) often take tamoxifen after surgery to prevent recurrence of the cancer and keep it from metastasizing to other parts of the body. Some patients, however, become resistant to the drug even though their tumors remain ER-positive.

To explore the mechanisms of this resistance, Suzanne Fuqua, Ph.D., professor of medicine in the Lester and Sue Smith Breast Center at Baylor College of Medicine in Houston and colleagues compared two groups of ER-positive tumors: four primary tumors from women who took tamoxifen and did not have a recurrence and five metastatic tumors from women taking tamoxifen whose tumors spread while they were on the drug. The authors found that Rho GDI-alpha was under-expressedits levels were lowin the women with tamoxifen-resistant metastatic disease. They validated the association of low Rho GDI-alpha with tamoxifen resistance in laboratory cells, in human tumors implanted in mice, and in genetic data from 250 women whose ER-positive breast tumors were treated with tamoxifen.

They also found that levels another proteinMTA2--rose markedly when Rho GD1-alpha dropped and that levels of MTA2 and Rho GDI-alpha combined predicted recurrence.

"These are the first data suggesting a tight, clinically important connection between the two pathways, Rho GDI-alpha and MTA2," the authors write. "Our data also suggest a possible mechanism, in which the loss of Rho GDI-alpha function promotes distant progression of breast tumors by triggering downstream molecules, such as MTA2, with metastasis-promoting activities."

In an accompanying editorial, Matthew J. Ellis, Ph.D. and Brian A. Van Tine, M.D. of Washington University in St. Louis note that other studies have found the proteins to be associated in various ways with breast cancer. But not all these previous findings are consistent with the findings of this study. "Thus, the status of Rho GDI-alpha as a marker of tamoxifen resistance is unclear," they write.

The editorialists also comment on the increasing number of genetic alterations emerging in breast cancer. "In the next several years," they write, "many entire breast cancer genomes will be published, revealing for the first time the enormous scale of the disruption of the human genome associated with the development of this disease." After that, they say, efforts to understand the functions of disrupted genes "will be essential for the next surge of progress."


'/>"/>

Contact: Caroline McNeil
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Researchers create drug to keep tumor growth switched off
6. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
7. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
8. Clemson researchers develop hands-free texting application
9. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
10. Researchers chart genomic map spanning over 2 dozen cancers
11. Researchers discover second protective role for tumor-suppressor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... , ... Aimed at nurses and employees in the health care world, this ... the nursing and health care industry. It also provides insight to the developing trends ... , As the nursing industry is coming out of one of the biggest recessions ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media ... Janet Yellen and company to wait until March 2017 for an interest rate increase, ... Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and ... according to court documents and SEC filings. A jury has returned a ... American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded ...
(Date:5/26/2016)... ... , ... Connor Sports, through its Connor Cares initiative, will continue ... Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and ... forms and levels of the game, Connor Sports has committed to a significantly increased ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is ... impact on long-term patient survival, reports a team of UPMC researchers in the ... in the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient ... bei Brustkrebs   QIAGEN N.V. (NASDAQ: ... gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit ... Assays für die Onkologie eingegangen zu sein. Ein ...
(Date:5/25/2016)... YORK , May 25, 2016  According to ... reached $381 billion in 2015.  Though these are ... plenty of opportunity for success for companies that ... in search of new growth prospects medical device ... on research and development (R&D) than do companies ...
(Date:5/25/2016)... NORTH CHESTERFIELD, Va. , May 25, 2016 ... commercially-available next-generation sequencing test for wounds and infections. ... fungi, ALL parasites, and select viruses. The test ... infected area. David G. ... advanced molecular testing to facilitate wound healing: "We ...
Breaking Medicine Technology: